An innovative inflammation-targeting platform for ulcerative colitis treatment
Wednesday, July 16, 2025
2:54 PM – 3:05 PM EDT
Introduction: Ulcerative colitis (UC) affects around 5 million people globally, and the development of drugs with safer profiles is crucial. Tofacitinib (1), an oral Janus kinase inhibitor, has been FDA-approved for UC. However, it carries an FDA black box warning due to its association with serious risks, including potential teratogenicity and fetolethality, serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis (2,3). We developed and validated a liposome/mannitol/hyaluronic acid platform for targeted tofacitinib delivery to the inflamed colon.
Learning Objectives:
At the completion of this activity, participants will know
Develop a mannitol-based liposomal formulation of tofacitinib for ulcerative colitis treatment.
The formulation passes the gastric environment and targets inflamed colon macrophages
It shows reduced dosing frequency, decreased drug toxicity, and improved therapeutic efficacy.
